# Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer

> **NCT04422392** · PHASE2 · TERMINATED · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 93 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed or Nab-paclitaxel
- **DRUG:** PD-1 antibody

## Key facts

- **NCT ID:** NCT04422392
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-13
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 93 (ACTUAL)
- **Why stopped:** since the CheckMate816 study is published in NEJM, enrolling patients becomes difficult
- **Last updated:** 2023-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04422392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04422392, "Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04422392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*